CPMD (Cannapharmarx) Risk Assessment

View and export this data going back to 1999. Start your Free Trial

What is Cannapharmarx Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cannapharmarx is: No Data: Cannot be evaluated.

Competitive Comparison of Cannapharmarx's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannapharmarx's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cannapharmarx's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Cannapharmarx (OTCPK:CPMD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cannapharmarx Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cannapharmarx's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannapharmarx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannapharmarx Inc (OTCPK:CPMD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3204-Rideau Place SW, Suite 302, Calgary, AB, CAN, T2S 1Z2

Website

https://www.cannapharmarx.com

Cannapharmarx Inc specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. The group evolved to focus on producing medical cannabis and craft products. Its products Unique Genetics, Craft Products, and Medical Cannabis.

Executives

Anthony Michael Panek	director	95 SOUTH STATE STREET, SUITE 2300, SALT LAKE CITY UT 84111
Dominic Colvin	director, officer: Chief Executive Officer	C/O CANNAPHARMARX, INC., 2 PARK PLAZA, SUITE 1200-B, IRVINE CA 92614
John Hamilton Cassels	officer: Chief Financial Officer	SUITE 500, 209 8TH AVENUE SW, CALGARY A0 T2P 1B8
Richard Dale Orman	director	302, 3204 RIDEAU PLACE SW, CALGARY A0 T2S1Z2
Andrew Clifford Steedman	officer: Chief Operating Officer	1131 RIVERDALE AVE SW, CALGARY A0 T2S 0Y9
Marc R Branson	director	977 KEITH ROAD, WEST VANCOUVER A1 V7T 1M6
Gary J Herick	10 percent owner	7609 RALSTON ROAD, ARVADA CO 80002
James F Samuelson	director	PO BOX 22, NEWPORT BEACH CA 92662
Matthew Nicosia	director, 10 percent owner	2 PARK PLAZA, SUITE 400, IRVINE CA 92614
Robert M Liess	director	2602 W. SAM ALLEN RD., PLANT CITY FL 33565
Mathew D Sherwood	director	P.O. BOX 4375, DILLON CO 80435
James E Smeeding	director	4029 GILBERT AVENUE, DALLAS TX 75219
Elie M Khalife	director	9447 E. CROSS CREEK STREET, WICHITA KS 67206
Steven J Rule	director	C/O CANNAPHARMARX, INC., ONE COLLINS DRIVE, SUITE 100, CARNEYS POINT NJ 08069
Alexander R Giaquinto	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920